Medical Devices

With a major funding round, Biobeat aims to replace bulky cuffs with a discreet patch, potentially revolutionizing hypertension care for millions.

With strong financials and new clinical data, medical device leader Penumbra is set to detail its growth strategy at healthcare's top investor event.

Treace Medical heads to the J.P. Morgan conference to showcase its surgical tech, facing tough questions on growth amid competition and market shifts.

With CEO David Endicott set to present at the J.P. Morgan Healthcare Conference, all eyes are on Alcon's strategy for innovation and market growth.

Profound Medical raises over $42M to advance its AI-powered, incision-free therapies for cancer and other diseases, signaling strong investor confidence.

Fresh off a successful IPO, Ceribell is set to showcase its revolutionary AI-powered EEG system, a device already changing outcomes in ICUs nationwide.

A 41-year-old mother's massive heart attack on Valentine's Day sparked a miraculous story of survival, advanced medicine, and profound gratitude.

As 'GLP-1 patch' ads flood social media for New Year's, an investigation reveals misleading marketing, a lack of science, and complex global companies.

The biopharma investment giant has now acquired 100% of the royalty stream for Roche's blockbuster SMA drug, a strategic move years in the making.

Veracyte prepares for the J.P. Morgan conference, where it will showcase its AI and genomic strategy amid strong financials and a competitive market.

As CooperCompanies heads to the J.P. Morgan conference, all eyes are on CEO Al White's strategic vision for its dual vision and women's health units.

The robotics firm is outsourcing key software development in a strategic move to reduce cash burn and speed its innovative surgical system to market.

With recent FDA approval, Belgian MedTech firm Nyxoah prepares for a pivotal presentation of its unique, battery-free sleep apnea implant at JPM.

After a swift restructuring, Modivcare emerges debt-light and privately owned, poised to aggressively invest in technology and transform supportive care.

The Danish firm scraps its 2025 revenue forecast, accepting a larger loss in a bold move to secure more lucrative future deals for its key drug candidates.

A new partnership aims to boost low colorectal cancer screening rates by combining trusted patient education with the promise of simpler blood-based tests.

Biotech pioneer Dr. Patrick Soon-Shiong is named a top influencer in oncology, boosting ImmunityBio amid strong sales and a promising drug pipeline.

A landmark journal issue introduces a new framework for facial rejuvenation, moving beyond outdated norms to embrace individualized, culturally sensitive care.

Genmab discontinues its 'encouraging' lung cancer drug, acasunlimab, in a bold strategic pivot to accelerate its most promising late-stage assets.

Setrusumab, a promising drug for Osteogenesis Imperfecta, failed to reduce fractures in key trials, triggering a market collapse and strategic overhaul.